Prenatal Cannabis Use Linked to Preterm Birth and Birth Defects in 1.28 Million Canadian Births

In a cohort of 1.28 million births across three Canadian provinces, prenatal cannabis use was associated with significantly increased risks of preterm birth, low birth weight, and major congenital anomalies.

Luke, Sabrina et al.·PloS one·2022·Strong EvidenceRetrospective Cohort
RTHC-04021Retrospective CohortStrong Evidence2022RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Retrospective Cohort
Evidence
Strong Evidence
Sample
Not reported

What This Study Found

Prenatal cannabis use (prevalence ~2%) was associated with increased risks of spontaneous preterm birth (aOR 1.80), medically indicated preterm birth (aOR 1.94), very preterm birth (aOR 1.73), low birth weight (aOR 1.90), small-for-gestational age (aOR 1.21), major congenital anomalies (aOR 1.71), cesarean section (aOR 1.13), and gestational diabetes (aOR 1.32). Female infants showed increased susceptibility for SGA and spontaneous preterm birth.

Key Numbers

1,280,447 births; ~2% cannabis prevalence; spontaneous preterm aOR 1.80; medically indicated preterm aOR 1.94; very preterm aOR 1.73; low birth weight aOR 1.90; congenital anomalies aOR 1.71; gestational diabetes aOR 1.32

How They Did This

Population-based retrospective cohort of 1,280,447 singleton births from three Canadian provincial registries (British Columbia, Ontario, Newfoundland/Labrador) from April 2012 to March 2019. Logistic regression adjusted for other substance use, sociodemographic factors, and comorbidities.

Why This Research Matters

This is one of the largest studies ever to examine prenatal cannabis outcomes, spanning nearly 1.3 million births across multiple provinces with adjustment for important confounders including other substance use.

The Bigger Picture

With cannabis legalization in Canada, this massive cohort provides some of the strongest population-level evidence that prenatal cannabis use carries meaningful risks for multiple birth outcomes.

What This Study Doesn't Tell Us

Cannabis use may be underreported. Cannot distinguish frequency, quantity, or method of cannabis use. Residual confounding possible despite statistical adjustment.

Questions This Raises

  • ?Why do female infants show greater susceptibility to some cannabis-related outcomes?
  • ?Does the timing of cannabis use during pregnancy (first vs third trimester) affect risk differently?

Trust & Context

Key Stat:
1.28 million births studied across 3 provinces
Evidence Grade:
Very large population-based cohort across multiple provinces with adjustment for key confounders. One of the largest prenatal cannabis studies to date.
Study Age:
Published in 2022
Original Title:
Cannabis use in pregnancy and maternal and infant outcomes: A Canadian cross-jurisdictional population-based cohort study.
Published In:
PloS one, 17(11), e0276824 (2022)
Database ID:
RTHC-04021

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-ControlFollows or compares groups over time
This study
Cross-Sectional / Observational
Case Report / Animal Study

Looks back at existing records to find patterns.

What do these levels mean? →

Frequently Asked Questions

How much does prenatal cannabis increase preterm birth risk?

This study found prenatal cannabis use nearly doubled the risk of spontaneous preterm birth (aOR 1.80) and medically indicated preterm birth (aOR 1.94) in a cohort of 1.28 million Canadian births.

Does prenatal cannabis cause birth defects?

The study found a 71% increased risk of major congenital anomalies (aOR 1.71) associated with prenatal cannabis use, though the observational design means it cannot definitively prove causation.

Read More on RethinkTHC

Cite This Study

RTHC-04021·https://rethinkthc.com/research/RTHC-04021

APA

Luke, Sabrina; Hobbs, Amy J; Smith, Michaela; Riddell, Catherine; Murphy, Phil; Agborsangaya, Calypse; Cantin, Christina; Fahey, John; Der, Kenny; Pederson, Ann; Nelson, Chantal. (2022). Cannabis use in pregnancy and maternal and infant outcomes: A Canadian cross-jurisdictional population-based cohort study.. PloS one, 17(11), e0276824. https://doi.org/10.1371/journal.pone.0276824

MLA

Luke, Sabrina, et al. "Cannabis use in pregnancy and maternal and infant outcomes: A Canadian cross-jurisdictional population-based cohort study.." PloS one, 2022. https://doi.org/10.1371/journal.pone.0276824

RethinkTHC

RethinkTHC Research Database. "Cannabis use in pregnancy and maternal and infant outcomes: ..." RTHC-04021. Retrieved from https://rethinkthc.com/research/luke-2022-cannabis-use-in-pregnancy

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.